Gemtuzumab Ozogamicin

Introduction Overview

Generic Name

gemtuzumab ozogamicin

Brand Name

Mylotarg

Dosage Form

Single-Dose Vial (4.5 mg)

Drug Class

CD33 monoclonal antibodies

Pharmacokinetics

Absorption: Mylotarg (gemtuzumab ozogamicin) is administered intravenously via infusion, bypassing the gastrointestinal tract, hence absorption through oral or other routes is not applicable. Following intravenous administration, the drug exhibits rapid plasma distribution. Distribution: The monoclonal antibody component specifically targets CD33-positive leukemic cells, allowing selective binding and internalization. Gemtozumab distributes primarily to circulating leukemic blasts and bone marrow compartments where CD33 expression is predominant. The drug’s distribution volume corresponds largely to plasma and extracellular fluid, consistent with the large molecule nature of monoclonal antibodies. Binding to CD33 mediates internalization, delivering the chemotherapeutic moiety calicheamicin intracellularly. Metabolism: Once internalized into the leukemic cells via CD33-mediated endocytosis, the calicheamicin conjugate is released into the lysosomal compartment where it undergoes activation to produce DNA strand breaks. The monoclonal antibody portion is catabolized by proteolytic enzymes into small peptides and amino acids, which enter natural catabolic pathways. The metabolism of the calicheamicin moiety involves reduction and enzymatic degradation, but detailed enzymatic pathways remain incompletely characterized. Elimination: The elimination of gemtuzumab ozogamicin occurs via proteolytic degradation within target cells and reticuloendothelial system, followed by renal and hepatic clearance of fragments. The elimination half-life is variable, often influenced by disease burden and CD33 expression levels. Clearance may be higher in patients with higher leukemic burden due to target-mediated drug disposition. The drug is not eliminated via classic renal excretion intact due to its large molecular size. Clinical pharmacokinetic studies indicate plasma clearance occurs over several days, with terminal half-lives typically in the range of days to weeks depending on dosing regimen and patient characteristics. Monitoring for toxicity and therapeutic response is critical due to variability in pharmacokinetics affected by disease state.

Dosage Forms

Available Dosage Forms: Mylotarg is commercially available as a single-dose vial containing 4.5 mg of gemtuzumab ozogamicin for intravenous infusion. Dosages for Adults and Adolescents: For adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), dosing in combination with chemotherapy includes 3 mg/m2 (max 4.5 mg) IV on Days 1, 4, and 7 during induction, and 3 mg/m2 IV on Day 1 during two consolidation cycles. As monotherapy, the induction dose is 6 mg/m2 IV on Day 1 and 3 mg/m2 IV on Day 8, followed by maintenance dosing of 2 mg/m2 IV on Day 1 every 4 weeks for up to 8 cycles. In the relapsed or refractory setting, monotherapy consists of 3 mg/m2 IV on Days 1, 4, and 7, with only a single course administered. Specific Patient Populations: Pediatric dosing varies by body surface area (BSA). For newly diagnosed AML in patients one month and older, dosing depends on BSA: patients <0.6 m2 receive 0.1 mg/kg, while those ≥0.6 m2 receive 0.3 mg/m2. For relapsed/refractory AML in patients aged 2 years and older, the dosing mirrors adult regimens: 3 mg/m2 IV on Days 1, 4, and 7. Special considerations include dose capping at a maximum of 4.5 mg per dose and careful patient monitoring. Premedications are recommended to reduce infusion reactions, including acetaminophen, diphenhydramine, and corticosteroids. Dosing adjustments may be necessary based on liver function and hematologic parameters, with clinicians advised to monitor closely for toxicity.

Mechanism Of Action

Gemtuzumab ozogamicin (Mylotarg) is a targeted therapy combining a humanized monoclonal antibody directed against CD33, a cell surface antigen expressed on leukemic myeloid cells, linked to a potent cytotoxic agent, calicheamicin. The molecular mechanism begins with the antibody portion binding with high specificity to CD33 antigen expressed on the surface of leukemic blast cells, allowing selective targeting of malignant cells while sparing non-CD33 expressing normal cells. Upon binding to CD33, the antibody-drug conjugate is internalized into the cell via receptor-mediated endocytosis. Within the acidic environment of the lysosome, the acid-labile linker is cleaved, releasing the calicheamicin warhead intracellularly. Calicheamicin is a highly potent enediyne antibiotic that binds to the minor groove of DNA and causes double-strand breaks by generating free radicals, leading to DNA scission. This DNA damage triggers apoptosis in leukemic cells through activation of the intrinsic mitochondrial apoptotic pathway. The specificity of delivery reduces systemic toxicity compared to conventional chemotherapy because the calicheamicin is released predominantly inside CD33-expressing cells. Clinically, this targeted cytotoxicity translates into the destruction of leukemic blasts with retention of bone marrow stem cells lacking CD33 expression. Compared with traditional chemotherapeutic agents, Mylotarg’s mechanism allows for selective leukemic cell kill, contributing to improved clinical outcomes in AML with fewer off-target effects. Research studies confirm that gemtuzumab ozogamicin induces apoptosis efficiently in CD33-positive AML cells both in vitro and in vivo. Clinical trials demonstrate its efficacy as monotherapy and in combination with chemotherapy, with the mechanism providing a rationale for dosing strategies that maximize leukemic blast eradication while minimizing systemic toxicity.

Pharmacological Actions

Selective binding to CD33 antigen on myeloid leukemic blasts.
Delivery of cytotoxic calicheamicin moiety to CD33-positive cells via antibody-drug conjugate.
Induction of DNA double-strand breaks leading to apoptosis of malignant cells.
Reduced toxicity to non-target cells due to selective internalization of drug.
Immunotherapeutic action combined with chemotherapeutic effect.
Modulation of leukemic cell burden in acute myeloid leukemia.
Synergistic activity in combination with standard chemotherapy agents daunorubicin and cytarabine.
Prolonged retention in bone marrow due to targeted action on leukemic cells.
Mylotarg’s mechanism results in reduction of leukemic blast counts and potential disease remission.
Potential disruption of leukemic cell proliferation and survival signaling via CD33 targeting.
Facilitation of apoptotic pathways through calicheamicin-induced DNA damage.
Contributes to clearance of residual disease in minimal residual disease contexts.
May sensitize leukemic cells to other cytotoxic agents when used in combination regimens.
Supports hematologic recovery by sparing hematopoietic stem cells lacking CD33.
Mylotarg’s targeted cytotoxicity provides a therapeutic approach with less systemic chemotherapy exposure.

Therapeutic Or Clinical Uses

Treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults.
Treatment of newly diagnosed CD33-positive AML in children aged one month and older.
Management of relapsed or refractory CD33-positive acute myeloid leukemia in adults.
Therapeutic option for relapsed or refractory AML in pediatric patients aged two years and older.
Used as a monotherapy or in combination with chemotherapy induction and consolidation regimens.
Adjunctive therapy incorporated with daunorubicin and cytarabine in AML treatment protocols.
Indicated for patients who have failed or are intolerant to other AML therapies.
Approved to target CD33-expressing leukemic blasts selectively, minimizing harm to normal cells.
Part of treatment regimens aiming to achieve remission and reduce leukemic burden.
Utilized to improve survival outcomes in AML patients with specific CD33 antigen expression.
Treatment aims to eradicate minimal residual disease and prevent relapse in AML.
Used under clinical protocols that include premedication and monitoring for infusion reactions.
Therapeutic use requires careful dosing and patient selection based on CD33 positivity.
Indicated for use with appropriate hepatic and hematological monitoring due to toxicity risks.
Part of frontline treatment strategies and salvage therapy options in AML management.

Side Or Adverse Effects

Increased risk of bleeding, including serious hemorrhagic events.
Potential for life-threatening liver damage such as veno-occlusive disease (hepatic sinusoidal obstruction syndrome).
Infusion-related reactions including fever, chills, hypotension, dyspnea, and chills occurring during or shortly after infusion.
Bone marrow suppression resulting in low blood cell counts: neutropenia, thrombocytopenia, and anemia.
Common hematologic toxicities such as fever, infection, and increased susceptibility to infections.
Mouth sores (mucositis) causing pain and difficulty swallowing.
Gastrointestinal side effects including nausea, vomiting, and constipation.
Headache and neurological symptoms potentially related to bleeding or toxicity.
Abnormal liver function tests indicative of hepatic stress or damage.
Signs of bleeding in the brain such as sudden numbness, weakness, severe headache, speech or vision difficulties.
Hypersensitivity reactions including rash, hives, angioedema, and anaphylaxis.
Fatigue, malaise, and unusual tiredness related to hematologic toxicity.
Potential electrolyte imbalances secondary to treatment or underlying disease.
Possibility of delayed toxicities requiring long-term monitoring.
Risk of fetal harm or teratogenic effects if administered during conception or pregnancy.

Precautions

Avoid use in patients with known hypersensitivity to gemtuzumab ozogamicin or its components.
Screen for and monitor liver function tests due to risk of hepatotoxicity and veno-occlusive disease.
Pre-treatment evaluation of complete blood counts to assess baseline bone marrow function.
Premedicate with acetaminophen, diphenhydramine, and corticosteroids to reduce infusion reactions.
Avoid in patients with uncontrolled infections or active bleeding.
Use effective contraception during treatment and for recommended durations after last dose due to teratogenicity risk.
Avoid breastfeeding during treatment and for at least one month post-therapy to prevent infant exposure.
Monitoring for signs of infusion-related hypersensitivity reactions during and after administration.
Assess electrolytes regularly, particularly potassium and magnesium, to prevent complications.
Careful patient selection in those with pre-existing liver disease or QT prolongation history.
Cytoreduction recommended prior to administration in patients with hyperleukocytosis to prevent complications.
Delay or adjust chemotherapy if significant toxicity or severe adverse events occur.
Close monitoring required for pediatric patients with weight and BSA-based dosing adjustments.
Avoid use in concurrent active stem cell transplantation without specialized protocols.
Clinical vigilance for early signs of bleeding or neurologic complications.

Warnings

Mylotarg can cause serious and potentially fatal liver toxicity, including veno-occlusive disease.
There is a significant risk of life-threatening bleeding complications during therapy.
Infusion reactions can be severe, necessitating emergency interventions and premedication.
Pregnancy exposure carries high risk of birth defects and fetal harm; contraception mandatory.
Mylotarg should only be administered by healthcare professionals experienced in AML treatment.
Concomitant use with other QT-prolonging agents increases risk of arrhythmias and sudden death.
Delayed hematologic recovery may occur, prolonging cytopenias and infection risk.
Mylotarg has a black box warning for hepatotoxicity and hemorrhagic events.
Use caution in patients with compromised hepatic or cardiac function.
Monitor for severe infusion-related hypersensitivity reactions including anaphylaxis.
Bleeding in critical organs such as brain may cause permanent damage or death.
Discontinue treatment immediately if severe hepatotoxicity or bleeding occurs.
Dose adjustments or treatment delays may be needed based on adverse event severity.
Avoid activities increasing injury risk due to impaired hemostasis.
Malfunction or contamination of intravenous administration may cause serious events.

Contraindication

Known hypersensitivity to gemtuzumab ozogamicin or any component of the formulation.
Severe active hepatic impairment or history of veno-occlusive disease may preclude use.
Uncontrolled active bleeding or severe coagulopathy conditions.
Pregnancy due to risk of fetal harm and teratogenicity.
Concurrent administration with other agents causing severe bone marrow suppression without close monitoring.
Caution or contraindication in patients with QT prolongation or familial long QT syndrome.
Patients with a history of serious infusion-related anaphylaxis to monoclonal antibodies.
Severe electrolyte imbalances not corrected prior to therapy initiation.
Known active infections contraindicating immunosuppressive therapies.
Inability to comply with premedication or monitoring requirements.
Patients with prior fatal reactions to gemtuzumab ozogamicin treatment.
Pediatric patients under 1 month of age due to insufficient safety data.
Use contraindicated in breastfeeding women during therapy and one month post-therapy.
Severe renal impairment precluding safe drug clearance (case-by-case basis).
Patients who have hypersensitivity to murine or other antibody components related to gemtuzumab.

Drug Interactions

Chemotherapeutic agents such as daunorubicin and cytarabine used in combination therapy can increase additive toxicity.
Other drugs prolonging QT interval may enhance cardiac arrhythmia risk when combined with Mylotarg.
Medications that impair hepatic function or are hepatotoxic can exacerbate liver toxicity.
Concomitant use with anticoagulants may increase bleeding risk.
Certain antifungal and antibiotic agents that affect CYP enzymes may alter metabolism indirectly.
Drugs causing myelosuppression can compound hematologic adverse effects.
Interactions with immunosuppressants may increase infection risk during treatment.
Medications altering electrolyte balance (e.g., diuretics) may worsen Mylotarg-related complications.
Oral contraceptives may have reduced effectiveness necessitating additional contraception methods.
Vitamins and herbal supplements with anticoagulant properties could increase bleeding tendencies.
Interactions with other monoclonal antibodies may affect immune response or increase hypersensitivity.
P-glycoprotein inducers or inhibitors may potentially affect cellular handling of antibody–drug conjugates.
Corticoids and antihistamines are used concomitantly to mitigate infusion reactions.
Potential interaction with antiretroviral therapy in patients co-infected with HIV requires monitoring.
Drugs affecting bone marrow function necessitate close hematologic monitoring when combined.

Preparations Of The Drug

Mylotarg is supplied as a sterile, preservative-free single-dose vial containing 4.5 mg gemtuzumab ozogamicin.
Vial intended for intravenous infusion preparation under aseptic conditions.
Reconstitution with sterile water for injection followed by dilution in appropriate IV fluids as per prescribing information.
Storage conditions include refrigeration at 2°C to 8°C and protection from light until use.
Once reconstituted and diluted, the solution should be used promptly or stored per stability guidelines.
Premedications including acetaminophen, diphenhydramine, and corticosteroids are recommended prior to infusion.
Prepared infusion solution must be administered slowly over at least two hours.
Healthcare providers monitor patients closely during and for at least one hour post-infusion for adverse reactions.
Dosing individualized by body surface area; maximum dose capped at 4.5 mg per infusion.
Preparation requires trained medical personnel experienced in handling monoclonal antibody therapies.
Instructions for dose calculation based on patient weight and body surface area are included in prescribing guidelines.
Handling precautions to avoid exposure to healthcare workers include use of gloves and precautions for antineoplastic agents.
Special instructions for patients with hepatic impairment to adjust dosing or delay therapy as needed.
Not intended for subcutaneous or intramuscular administration.
Discard unused portions in accordance with institutional protocols for cytotoxic drug disposal.